JANX- Janux Therapeutics, Inc.

Name: Janux Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Janux Therapeutics, Inc. (JANX) has 16 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. JANX is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Campbell David Alan	338.1K	$4.92M	-
Other	Diraimondo Thomas	155.8K	$2.27M	-
Other	McIver Zachariah	101.5K	$1.48M	-
Other	Winter Charles M.	100.1K	$1.46M	-
Other	Meyer Andrew Hollman	83.1K	$1.21M	-

Activity

Buys and sells only

Transactions

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 2, 2026	Dobek Maria	Vice President, Accounting	Sell	1,462	$13.73	$20,073.26	-8.7%	+8.7%	-
Jan 2, 2026	Diraimondo Thomas	Chief Scientific Officer	Sell	2,505	$13.73	$34,393.65	-2.0%	+8.7%	-
Jan 2, 2026	Campbell David Alan79	President And CEO	Sell	8,072	$13.73	$110,828.56	-2.8%	+8.7%	-
Jan 2, 2026	Winter Charles M.	Chief Technical Officer	Sell	2,401	$13.73	$32,965.73	-3.0%	+8.7%	-
Jan 2, 2026	McIver Zachariah	Chief Medical Officer	Sell	2,714	$13.73	$37,263.22	-10.4%	+8.7%	-
Jan 2, 2026	Meyer Andrew Hollman86	Chief Business Officer	Sell	1,879	$13.73	$25,798.67	-2.2%	+8.7%	-
Dec 1, 2025	Meyer Andrew Hollman86	Chief Business Officer	Sale+OE	3,333	$32.98	$109,929.10	-1.9%	-60.5%	-
Nov 14, 2025	Meyer Andrew Hollman86	Chief Business Officer	Sale+OE	3,333	$30.00	$99,990.00	-3.8%	-55.2%	-
Oct 28, 2025	Meyer Andrew Hollman86	Chief Business Officer	Sale+OE	16,665	$30.06	$500,986.56	-16.9%	-50.8%	-
May 1, 2025	Meyer Andrew Hollman86	Chief Business Officer	Sale+OE	3,333	$32.03	$106,744.55	-2.0%	-24.4%	-55.3%

Page 1Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC